Accreditation

AACE Communities MENA Conference

Event start date: 11/11/2022
Credit claim deadline: 12/31/2022

 

Statement of Need

AACE Communities MENA Conference is designed to provide a forum for medical professionals to enhance their patient-centered approaches, to help optimize and personalize their patient outcomes by immersing themselves in the most relevant clinical approaches and technology advances.

 

Target Audience

This program targets all medical professionals that care for patients with endocrine disorders including endocrinologists, cardiologists, nephrologists, primary care physicians, advanced providers, nurses, diabetes educators, and pharmacists. The program is also intended for health care professionals at any stage in their career.

 

Learning Objectives

By the end of the meeting, participants will be able to:

  • Discuss the latest clinical practice guidelines on endocrine disorders, including diabetes mellitus, diabetes technology, obesity, pituitary and adrenal disorders, thyroid cancer and bone metabolism.
  • Summarize key characteristics of evidence-based assessment and management options for patients with endocrine disorders and endocrine neoplasia.
  • Apply multidisciplinary approaches on the management and treatment options for patients with endocrine disorders for improved patient outcomes.
  • Formulate management plans that include optimal team-based, patient centered care of patients with endocrine disorders.

 

Accreditation and Designation Statements

ACCME

The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Endocrinology (ACE) designates this live activity for a maximum of 14.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure and Conflicts of Interest Policy

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 

 

Planners

Planner NameIneligible CompanyRelevant Financial Relationship
Susan Samson, MD, PhD, FACEChiasma/Amryt
Corcept
Chiasma/Amryt
Stock Ownership
Stock Ownership
Consultant
Jaime Almandoz, MDNovo Nordisk
Eli Lilly
Consultant
Consultant
Vinaya Simha, MDPfizer Consultant
Sarah Nadeem, MD, FACE Novo NordiskConsultant
Nasreen Alfaris, MDNovo NordiskSpeakers Bureau, Consultant

 

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

 

Faculty Disclosures

Faculty NameIneligible CompanyRelevant Financial Relationship
Zahid Ahmad, MDAkcea, RegeneronConsultant
Diane Donegan, MDCorcept, Acendis, Amyrt
Recordati, Acendis
Research Funding
Consultant
Barton Duell, MDRegeneron, Regenxbio, Retrophin (Travere)
Akcea, Amryt, Novartis, Kaneka, Regeneron
Research Funding
Consultant
W. Timothy Garvey, MDNovo Nordisk, Epitomee, Pfizer, and Eli Lilly
Eli Lilly, Novo Nordisk, Pfizer, JAZZ Pharmaceuticals, Boehringer-Ingelheim, Fractyl, and Alnylam
Principal investigator - no direct payments received
Consultant
Kristien Boelaert, MDLillyConsultant
Adriana Ioachimescu, MDAmryt (former Chiasma), Xeris (former Strongbridge) and Recordati Rare Diseases
Amryt (former Chiasma), Xeris (former Strongbridge), HRA Pharma and Recordati Rare Diseases
Research Funding
Consultant
Mohamed Hassanein ,MDNovo, Lilly, Sanofi, Novartis, BI, MSD, Servier and Abbott
Nova, Sanofi, Lilly, BI
Speaker Bureau
Consultant
Aisha Sheikh, MDNovoNordisk, Lily, Sanofi Aventis, Martin Dow, and HorizonSpeaker Honoraria
Khalid Al Waili, MDSanofi, Abbott, and NovartisSpeaker Bureau
Ashish Chintakuntlawar, MDEisai, Genmab, AstraZeneca, PDS biotech, Rakuten Medical
HRA pharma, Rakuten Medical
Research Funding - Institutional
Consultant - Institutional
Amir Babiker, MDNovo Nordisk
Insulet (Omnipod)
Speaker Bureau
Consultant

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Reviewers

None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.